Novanta Completes Acquisition of Riverpoint Medical: Strategic Expansion into High-Growth Medical Consumables
Date: July 27, 2026
Key Highlights
- Novanta Inc. (Nasdaq: NOVT) has completed its acquisition of Riverpoint Medical from Arlington Capital Partners.
- Riverpoint Medical is a leader in minimally invasive surgical consumables, serving high-growth markets such as sports medicine, trauma, and cardiovascular surgery.
- The acquisition is expected to double Novanta’s recurring medical consumables revenue to approximately \$300 million and increase medical end-market exposure to 60% of total company revenue.
- Novanta anticipates unlocking a \$2 billion incremental addressable market through shared OEM customer relationships and an expanded, FDA-registered manufacturing footprint.
- The deal is expected to be immediately accretive to Novanta’s organic growth, adjusted gross margins, adjusted EBITDA growth and margins, and cash flows.
- Projected contribution of \$0.18 to \$0.25 to adjusted EPS in 2027, with more financial details to be shared in the company’s upcoming second quarter earnings call.
- Riverpoint Medical will be integrated into Novanta’s Medical Solutions operating segment.
Strategic Rationale and Shareholder Impact
The acquisition of Riverpoint Medical is a major strategic move for Novanta, targeting fast-growing segments within the surgical consumables market. According to Matthijs Glastra, Novanta’s Chair & CEO, Riverpoint Medical delivers revenue and cash flow growth at twice the rate of Novanta’s legacy business. This transaction is expected to not only enhance topline growth but also significantly diversify Novanta’s revenue mix, with medical consumables becoming a larger proportion of total sales.
The deal is positioned to unlock a substantial \$2 billion incremental addressable market through cross-leveraged OEM relationships and expanded FDA-registered manufacturing capabilities, potentially driving higher-margin and accelerated growth for the combined entity.
Financial Returns and Outlook
- The transaction is expected to yield a high single-digit return on invested capital by year three and reach Novanta’s return hurdle rate by year five.
- It will be immediately accretive to key metrics, notably organic growth, adjusted gross margin, and adjusted EBITDA growth and margin.
- The acquisition is projected to add \$0.18 to \$0.25 in adjusted EPS for 2027, which is the first full year post-integration.
- Further impact on 2026 financials will be disclosed in the upcoming Q2 earnings call.
This news is highly relevant and potentially price-sensitive for shareholders, given the scale of the transaction, the expected accretion to earnings, and the expansion into high-growth, high-margin markets—factors that can meaningfully affect Novanta’s share value.
About Riverpoint Medical
Riverpoint Medical, based in Portland, Oregon, designs and manufactures IP-protected, private-label surgical consumables for leading medical OEM customers. Its portfolio includes advanced suture anchors, implantable materials, sutures, and surgical instruments, with a primary focus on sports medicine and cardiovascular surgery. The company’s competitive edge is grounded in proprietary material science, innovative coating technologies (including osteoconductive materials), and the capability to manage the FDA’s 510(k) clearance process end-to-end for OEM partners. Manufacturing facilities are located in Portland, Oregon, and San Jose, Costa Rica.
About Novanta
Novanta is a global technology solutions provider specializing in medical, life sciences, and advanced industrial markets. The company is known for its proprietary expertise in precision medicine, advanced manufacturing, robotics, and automation. Novanta’s solutions are tailored for demanding OEM applications, with a strong culture of innovation and customer success. Novanta’s shares are traded on Nasdaq under the symbol “NOVT.”
About Arlington Capital Partners
Arlington Capital Partners is a Washington, D.C.-area private equity firm with a focus on government-regulated sectors, including healthcare and technology. Since its inception in 1999, Arlington has invested in over 200 companies, with over \$14 billion in committed capital and is currently investing out of its \$6 billion Fund VII.
Forward-Looking Statements
The press release contains forward-looking statements regarding the anticipated benefits, integration, and financial impact of the Riverpoint Medical acquisition. These statements are subject to risks, including integration challenges, realization of expected synergies, and other factors detailed in Novanta’s filings with the SEC. Investors should not place undue reliance on these projections.
Contact Information
For additional information, contact Novanta Investor Relations at (781) 266-5137 or [email protected]. Media inquiries can be directed to [email protected].
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All forward-looking statements are subject to risks and uncertainties as described. Investors should perform their own due diligence and consult financial advisors before making investment decisions.
